Management of Patients with Elevated ASCVD Risk and Hypercholesterolemia

Risk Assessment and Classification

The American College of Cardiology recommends that patients with a 10-year ASCVD risk of 13.3% be classified as intermediate risk, warranting aggressive risk factor management 2
The presence of multiple risk factors, including hypertension and hypercholesterolemia, indicates a need for pharmacological intervention, according to the American College of Cardiology 1, 3

The American College of Cardiology recommends initiating moderate to high-intensity statin therapy to achieve a 30-49% reduction in LDL-C for intermediate-risk patients 1, 4
High-intensity statin therapy, such as atorvastatin 40-80 mg or rosuvastatin 20-40 mg, may be considered for patients with additional risk enhancers beyond the calculated 13.3% risk, as suggested by the American College of Cardiology 5, 2
The American College of Cardiology notes that high-intensity statins typically lower LDL-C by ≥50%, while moderate-intensity statins lower LDL-C by 30-49% 1

The American College of Cardiology recommends initiating appropriate antihypertensive therapy based on current blood pressure guidelines 2
The target blood pressure should be <130/80 mmHg for patients with elevated ASCVD risk, according to the American College of Cardiology 2

The American College of Cardiology recommends a Mediterranean, DASH, or plant-based diet to help lower both cholesterol and blood pressure 2
The American College of Cardiology suggests 150-300 minutes of moderate-intensity or 75-150 minutes of vigorous-intensity physical activity per week 2
Smoking cessation counseling and consideration of pharmacotherapy, such as nicotine replacement, varenicline, or bupropion, are recommended for patients who smoke, according to the American College of Cardiology 2

The American College of Cardiology recommends obtaining a lipid panel 4-12 weeks after initiating statin therapy to assess response 1
Regular blood pressure monitoring is essential to ensure adequate control, as suggested by the American College of Cardiology 2

The American College of Cardiology recommends evaluating the potential for ASCVD risk reduction, adverse effects, drug-drug interactions, and considering patient frailty before initiating therapy in patients >75 years of age 1, 4
The presence of diabetes further supports the use of at least moderate-intensity statin therapy, according to the American College of Cardiology 2
The American Diabetes Association notes that hypertriglyceridemia (≥175 mg/dL) is a factor favoring initiation or intensification of statin therapy 7